Effect of Probiotic Adjuvant Therapy on Improvement of Clinical Symptoms & Interleukin 6 Levels in Patients With Schizophrenia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective This study aims to examine the effect of giving probiotic adjuvant therapy on improving clinical symptoms & IL-6 levels in patients with schizophrenia.Methods This research was a double-blind, placebo-controlled trial conducted at Dadi Psychiatric Hospital, South Sulawesi Province, Indonesia in November–December 2021. The sample of the research was patients with schizophrenia undergoing hospitalization who received therapeutic doses of risperidone with a total of 21 samples in each treatment and control group. Research subjects were measured with Positive and Negative Syndrome Scale (PANSS) at baseline, 2nd, 4th, and 6th weeks. The treatment group received one capsule/12 hours/oral of probiotics for six weeks and the control group received 1 capsule/12 hours/oral placebo for 6 weeks. In addition, two measurements of IL-6 using enzyme-linked immunosorbent assay were performed in both groups, namely at the beginning of week 0 and the end of the 6th week.Results We found the decrease in the PANSS value which described the improvement in clinical symptoms of the schizophrenic group after receiving therapeutic doses of antipsychotics and probiotic capsules or the treatment group as well as the schizophrenia group receiving therapeutic doses of antipsychotics and placebo capsules or the control group.Conclusion Improvements in clinical symptoms and decreased levels of IL-6 in the group of patients with schizophrenia who received risperidone with probiotic adjuvant therapy were better than in the group of patients with schizophrenia who received risperidone without probiotics as adjuvant therapy.
Abstract
Objective This study aims to examine the effect of giving probiotic adjuvant therapy on improving clinical symptoms & IL-6 levels in patients with schizophrenia.Methods This research was a double-blind, placebo-controlled trial conducted at Dadi Psychiatric Hospital, South Sulawesi Province, Indonesia in November–December 2021. The sample of the research was patients with schizophrenia undergoing hospitalization who received therapeutic doses of risperidone with a total of 21 samples in each treatment and control group. Research subjects were measured with Positive and Negative Syndrome Scale (PANSS) at baseline, 2nd, 4th, and 6th weeks. The treatment group received one capsule/12 hours/oral of probiotics for six weeks and the control group received 1 capsule/12 hours/oral placebo for 6 weeks. In addition, two measurements of IL-6 using enzyme-linked immunosorbent assay were performed in both groups, namely at the beginning of week 0 and the end of the 6th week.Results We found the decrease in the PANSS value which described the improvement in clinical symptoms of the schizophrenic group after receiving therapeutic doses of antipsychotics and probiotic capsules or the treatment group as well as the schizophrenia group receiving therapeutic doses of antipsychotics and placebo capsules or the control group.Conclusion Improvements in clinical symptoms and decreased levels of IL-6 in the group of patients with schizophrenia who received risperidone with probiotic adjuvant therapy were better than in the group of patients with schizophrenia who received risperidone without probiotics as adjuvant therapy.
참고문헌 (27)
- Severance EG, "Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling", Schizophr Res, 176, pp.23~35 (2016)
- Naufal F, "Psychobiotics: role of gut microbiota in mental health", Medical Profession Journal of Lampung, 10, pp.545~550 (2020)
- Nagamine T, "The effect of probiotics on bowel movement and metabolic parameters in schizophrenia patients: a retrospective chart review", Biosci Microbiota Food Health, 39, pp.197~198 (2020)
- Nemani K, "Schizophrenia and the gut-brain axis", Prog Neuropsychopharmacol Biol Psychiatry, 56, pp.155~160 (2015)
- Ng QX, "A meta-analysis of the use of probiotics to alleviate depressive symptoms", J Affect Disord, 228, pp.13~19 (2018)
- Ng QX, "A systematic review of the effect of probiotic supplementation on schizophrenia symptoms", Neuropsychobiology, 78, pp.1~6 (2019)
- Sivamaruthi BS, "Probiotics in human mental health and diseases-a mini-review", Trop J Pharm Res, 18, pp.889~895 (2019)
- Sinaga BR, "Skizofrenia dan diagnosis banding" (2007), Balai Penerbit FKUI
- clinical psychiatry, "Kaplan and Sadock’s synopsis of psychiatry behavioural sciences", pp.2015, Sadock BJ
- Li R, "Why sex differences in schizophrenia?", J Transl Neurosci (Beijing), 1, pp.37~42 (2016)
- Dickson H, "Academic achievement and schizophrenia: a systematic metaanalysis", Psychol Med, 50, pp.1949~1965 (2020)
- Davidson L, "Remission and recovery in schizophrenia: practitioner and patient perspectives", Schizophr Bull, 34, pp.5~8 (2008)
- Novitayani S, "Characteristic of schizophrenic patient with experience rehospitalization", Idea Nursing Journal, 7, pp.23~29 (2016)
- Fahrul MA, "Prodi Farmasi, untad Lab. Farmakologi dan Farmasi Klinik, Prodi Farmasi, Untad 1", Online J Nat Sci, 3, pp.40~46 (2014)
- Widyarti EP, "The analysis of prognostic factors in patients with schizophrenia at the mental hospital in Sambang Lihum", Homeostasis, 2, pp.509~518 (2020)
- Herlina T, "Atypical antipsychotic induced weight gain in schizophrenic patients", Indones J Clin Pharm, 10, pp.57~61 (2021)
- Turnbaugh PJ, "The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice", Sci Transl Med, 1, pp.6ra14~ (2009)
- Saidah S, "Levels of interleukin 6 as a predictor of metabolic syndrome in schizophrenic patients receiving combination therapy of typical and atypical antipsychotics", Open Access Maced J Med Sci, 9, pp.600~607 (2021)
- Miettinen M, "Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria", Infect Immun, 64, pp.5403~5405 (1996)
- Biagi E, "Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians", PLoS One, 5, pp.e10667~ (2010)
- Leung K, "Gut microbiota: a modulator of brain plasticity and cognitive function in ageing", Healthcare (Basel), 3, pp.898~916 (2015)
- Sarkar A, "Psychobiotics and the manipulation of bacteria-gut-brain signals", Trends Neurosci, 39, pp.763~781 (2016)
- Adikari AM, "Psychotropic properties of probiotics:a systematic review", Int J Public Health Clin Sci, 6, pp.18~34 (2019)
- Dinan TG, "Psychobiotics: a novel class of psychotropic", Biol Psychiatry, 74, pp.720~726 (2013)
- Nagamine T, "Probiotics reduce negative symptoms of schizophrenia: a case report", Int Med J, 19, pp.67~68 (2012)
- Suganya K, "Gut–brain axis: role of gut microbiota on neurological disorders and how probiotics", prebiotics beneficially modulate microbial and immune pathways to improve brain functions, 2020, pp.21, 7551~
- Sudo N, "Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice", J Physiol, 558(Pt 1), pp.263~275 (2004)